Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mebendazole is a broad-spectrum anthelmintic drug used to treat a variety of intestinal worm infections, including pinworm (Enterobius vermicularis), whipworm (Trichuris trichiura), roundworm (Ascaris lumbricoides), and hookworm (Ancylostoma duodenale, Necator americanus)[1][2][3][5][6]. It works by inhibiting the formation of microtubules in parasitic worms, which disrupts glucose uptake and depletes their energy stores, ultimately leading to their death[1][6][8]. Mebendazole is poorly absorbed from the gastrointestinal tract and acts primarily within the gut. It is available as chewable tablets or oral suspension for both adults and children. The drug was originally developed by Janssen Pharmaceutica[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mebendazole.